Over the past 3 decades, pharmacists have become integrated members of multidisciplinary teams. To recognize the value of the role of pharmacists in improving patient outcomes and safety in cardiac care, the American Heart Association (AHA) will offer pharmacists a session focused specifically on them at this year?s AHA Scientific Sessions in Orlando, Fla.
Over the past 3 decades, pharmacists have become integrated members of multidisciplinary teams. To recognize the value of the role of pharmacists in improving patient outcomes and safety in cardiac care, the American Heart Association (AHA) will offer pharmacists a session focused specifically on them at this year’s AHA Scientific Sessions in Orlando, Fla.
AHA with the American College of Clinical Pharmacy’s (ACCP) Cardiology Practice and Research Network (Cardiology PRN), along with members of the AHA Clinical Pharmacology Committee will collaborate to target this session to the approximately 400 pharmacists who attend AHA annually.
The session will offer information on the specialized roles of pharmacists in the cardiovascular setting, demonstrate the impact of pharmacist interventions on healthcare, describe successful clinical programs, and provide insight into how the pharmacist can most effectively manage conditions such as hyperlipidemia, heart failure, hypertension, and anticoagulation, to improve patient outcomes and safety.
The session, called Improving Clinical Outcomes and Patient Safety Through Interventions by Clinical Pharmacists, will take place on Sunday, November 13, from 5:30 to 6:45 pm and will be co-moderated by Sheryl L. Chow, PharmD, BCPS and Robert L. Page, II, PharmD, MSPH, BCPS, FCCP, FAHA.
The program outline includes:
• Cardiac Risk Reduction: Moving Beyond Statins
• Heart Failure: More Than Titrating Doses
• Hypertension: Getting Blood Pressure to Goal
• Anticoagulation: Preventing Bleeding While Preventing Stroke
• Q&A Discussion
For more information and to register, interested pharmacists can go to the Scientific Sessions on the American Heart Association website.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More